Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 16, 2025Diabetes Obesity and Metabolism

Novel oral agents in anti‐obesity pharmacotherapy: A narrative review

View Full Paper
Ask AI
Bookmark
Share

Authors

ABAssaf BuchRERoy EldorRERoy Eldor

Discussion

Loading...

Member takes

Overview

This narrative review highlights advances in oral agents and their potential in obesity treatment, suggesting improved patient management.

Key Points

  • Novel oral agents for obesity have shown potential for achieving significant weight loss of ≥10% in trials.
  • Oral GLP-1 RAs and non-incretin therapies target mechanisms like the melanocortin-4 receptor for effective treatment.
  • Research includes randomized controlled trials and emerging oral compounds not yet FDA approved, expanding treatment options.
  • These therapies may enhance patient adherence and satisfaction while complementing existing injectable treatments for long-term management.

Cite This Study

Buch et al. (2025) studied this question.

synapsesocial.com/papers/689a02c3e6551bb0af8cca9fhttps://doi.org/10.1111/dom.16618
View Full Paper
Ask AI
Bookmark
Share